FDA approves ruxolitinib cream 1.5% to treat nonsegmental vitiligo

Retrieved on: 2022-07-19 15:24:13

Tags for this article:

Click the tags to see associated articles and topics

FDA approves ruxolitinib cream 1.5% to treat nonsegmental vitiligo. View article details on hiswai:

Excerpt

Melanocytes are attacked and destroyed by the body's immune system and can occur anywhere in the body.2. Ruxolitinib provides relief to patients ...

Article found on: www.contemporarypediatrics.com